Biomedical Materials,
Год журнала:
2024,
Номер
19(2), С. 025017 - 025017
Опубликована: Янв. 12, 2024
Abstract
Nanomedicine
often
failed
clinically
to
show
therapeutic
efficacy
due
reduced
particle
circulation
and
enhanced
capture
by
the
reticuloendothelial
system,
including
liver.
Developing
novel
immunomodulatory
surface
coating
can
prevent
macrophage
increase
of
nanomedicine,
resulting
in
higher
efficiency.
Herein,
we
demonstrate
development
small
molecule
(RZA15)
with
triazole
functionality
using
copper-catalyzed
click
chemistry
conjugate
onto
spherical
polystyrene
nanoparticles
(NPs)
amide
coupling
reactions,
achieving
blood
lesser
uptake
nanoconjugates
(NCs).
In
this
work,
evaluated
effectiveness
RZA15
for
NPs
100
nm
size,
which
is
commonly
utilized
various
drug
delivery
applications,
compared
poly(ethylene)glycol
coatings.
Several
NC
formulations
were
analyzed
vitro
normal
cells
cell
viability
cellular
studies.
studies
demonstrated
NCs
following
coating.
Finally,
vivo
,
blood-circulation,
pharmacokinetics,
biodistribution
performed
C57BL/6J
mouse
model
that
endorsed
substantial
role
reducing
liver
spleen
results
extended
blood.
Coating
molecules
severely
enhance
potential
effects
nanomedicine
at
lower
doses
near
future.
Pharmaceuticals,
Год журнала:
2024,
Номер
17(3), С. 315 - 315
Опубликована: Фев. 28, 2024
Cancer
continues
to
pose
one
of
the
most
critical
challenges
in
global
healthcare.
Despite
wide
array
existing
cancer
drugs,
primary
obstacle
remains
selectively
targeting
and
eliminating
cells
while
minimizing
damage
healthy
ones,
thereby
reducing
treatment
side
effects.
The
revolutionary
approach
utilizing
nanomaterials
for
delivering
therapeutic
agents
has
significantly
enhanced
efficacy
safety
chemotherapeutic
drugs.
This
crucial
shift
is
attributed
unique
properties
nanomaterials,
enabling
nanocarriers
transport
tumor
sites
both
passive
active
modes,
drug
elimination
from
delivery
systems.
Furthermore,
these
can
be
designed
respond
internal
or
external
stimuli,
thus
facilitating
controlled
release.
However,
production
nanomedications
therapy
encounters
various
that
impede
progress
this
field.
review
aims
provide
a
comprehensive
overview
current
state
nanomedication
treatment.
It
explores
variety
focusing
on
their
are
overcoming
limitations
conventional
chemotherapy.
Additionally,
delves
into
functionalities
nanocarriers,
highlighting
significant
impact
evolution
nanomedicine.
also
critically
assesses
recent
advancements
systems,
covering
range
innovative
methodologies.
Finally,
succinctly
addresses
encountered
developing
nanomedications,
offering
insightful
perspectives
guide
future
research
Future Journal of Pharmaceutical Sciences,
Год журнала:
2024,
Номер
10(1)
Опубликована: Янв. 5, 2024
Abstract
Background
Medical
fraternity
are
continuously
pitching
toward
the
development
of
novel
mechanisms
to
combat
menace
cancer
and
enhance
efficacy
prevailing
molecules.
During
drug
phase,
majority
new
molecular
entity
pose
a
threat
due
hydrophobic
nature,
that
compromises
its
bioavailability
upon
administration.
These
suboptimal
accumulation
low
loading
hampers
clinical
translation
in
therapy.
Main
body
abstract
Nanotechnology
with
valuable
advantages
create
possibilities
accelerate
treatment.
Compared
matrix-based
formulations,
nanocrystals
(NCs)
smaller
size,
high
loading,
active
targeting,
extended
circulation,
great
structural
stability,
tailored
dissolution,
being
carrier
free
have
sparked
lot
interest
delivery.
Many
drugs
were
explored
as
NCs
such
as—doxorubicin,
paclitaxel,
campothecin
so
on.
However,
premature
leakage
clearance
by
mononuclear
phagocytosis
system
lead
some
obstacles
applications
NCs.
Conclusion
In
recent
years,
strategies
leading
surface
modification
applied
improve
uncontrolled
release
targeting
efficiency
tumor
cells.
The
current
review
sheds
light
on
various
properties
nanocrystals,
brief
insights
fabricating
techniques,
approaches
for
NCs,
their
imaging
therapeutics.
RSC Advances,
Год журнала:
2024,
Номер
14(21), С. 14704 - 14715
Опубликована: Янв. 1, 2024
Quantum
interference
(QI)
is
one
of
the
most
important
phenomena
that
affects
charge
transport
through
single
molecules.
The
effect
a
constructive
and
destructive
quantum
on
electronic,
thermoelectric
spectroscopic
properties
oligo(phenyleneethynylene)
based-molecular
junctions
has
been
investigated
using
combination
density
functional
theory
(DFT)
methods,
tight
binding
(Hückel)
modelling
(TBHM)
(QTT).
Molecules
with
carbonyl,
diphenyl,
ethane
ethynylferrocene
substituents
show
(DQI),
which
enhances
these
molecules
making
them
promising
materials
for
applications.
Pharmaceutical Development and Technology,
Год журнала:
2025,
Номер
unknown, С. 1 - 12
Опубликована: Апрель 25, 2025
The
purpose
of
this
study
was
to
investigate
the
impact
glycyrrhizic
acid
(GL)
concentrations
on
in
vitro
and
vivo
behavior
quercetin
(QT)
nanocrystals
stabilized
by
GL
(QT-NCs/GL),
with
a
particular
focus
its
influence
liver
targeted
drug
delivery.
QT-NCs/GL
similar
particle
size
around
200
nm
were
successfully
prepared
media
milling
technique
using
different
GL,
which
10%,
20%
40%
(w/w)
QT.
morphology,
crystalline
state,
solubility,
release,
as
well
pharmacokinetic
distribution
following
intravenous
administration
investigated.
An
oval
short
rod
nanoparticles
observed
for
all
scanning
electron
microscope.
X-ray
powder
diffraction
results
showed
remained
but
reduced
crystallinity
found
increase
concentrations.
All
exhibited
significant
solubility
release
improvement
QT
compared
raw
There
no
difference
plasma
concentration-time
curve
parameters
after
QT-NCs/GL,
except
that
AUC0∼t
QT-NCs/GL-10%
significantly
higher
than
QT-NCs/GL-20%.
rapidly
maximum
concentration
more
750
μg/g
at
5
min
administration,
three
formulations
order:
QT-NCs/GL-40%
>
QT-NCs/GL-20%
QT-NCs/GL-10%.
It
could
be
concluded
delivery
used
may
contribute
Journal of Materials Chemistry B,
Год журнала:
2024,
Номер
12(6), С. 1579 - 1591
Опубликована: Янв. 1, 2024
Nitric
oxide
(NO)
gas
molecules
have
demonstrated
remarkable
anti-tumor
effects
and
minimal
susceptibility
to
drug
resistance,
establishing
as
a
promising
modality
for
effective
tumor
treatment.
However,
how
realize
its
stable
efficient
delivery
in
vivo
is
still
challenge.
In
this
study,
we
developed
heat-responsive
biomimetic
nano
erythrocyte
(M/B@R)
by
loading
NO
donor
(BNN6)
onto
mesoporous
Prussian
blue
(M-PB)
subsequently
enveloping
them
with
red
blood
cell
membranes.
The
preserved
integrity
of
the
membrane
(RBCm)
structure
could
ensure
excellent
biosafety,
prolong
circulation
time
within
bloodstream
then
enhance
accumulation
BNN6
at
sites.
When
M/B@R
stimulated
near-infrared
light
(NIR-II,
808
nm)
irradiation,
nanoparticle
generate
significant
heat
photothermal
therapy
(PTT)
characteristic
NIR
absorption
M-PB
also
be
efficiently
released.
generated
further
facilitates
formation
ONOO-,
highly
toxic
species
tumors,
while
alleviating
hypoxia.
Remarkably,
M/B@R,
excitation
source,
induces
combined
lethality
through
hyperthermia,
DNA
damage,
hypoxia
relief.
This
novel
combination
strategy
provides
new
avenue
PTT/NO-induced
cancer
therapy.
Advanced Therapeutics,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 2, 2024
Abstract
Research
into
mechanisms
and
potential
applications
of
nanomaterials
in
medicine
has
expanded
steadily
recent
decades,
with
increasing
translational
focus.
Development
costs,
including
for
clinical
trials,
are
often
cited
as
factors
limiting
the
viability
novel
nanomedicines,
especially
compared
to
small
new
molecular
entities
(NMEs)
therapeutic
biologics.
Yet,
date,
there
been
no
systematic
investigation
programs
or
costs
translating
commercializing
nor
a
comparison
NMEs
biologics,
support
these
claims.
Here,
nanomedicines
approved
by
United
States
Food
Drug
Administration's
Center
Evaluation
(CDER)
from
2011
2023
systematically
identified
categorized.
Nanomedicines
were
formulations
where
submicron
particle
size
contributes
product
function.
Like
biologics
NMEs,
most
frequently
oncological
indications.
Notably,
all
anti‐cancer
indicated
treat
orphan
diseases,
which
is
representative
occupy
pharmaceutical
niches
treating
diseases
affecting
smaller
patient
cohorts.
The
median
estimated
cost
pivotal
trials
47%
that
same
timeframe.
findings
indicate
higher
manufacturing
nanomedicine
development
may
be
mitigated
savings
elsewhere,
viability.
